Sight Sciences SGHT
Sight Sciences, Inc. · Nasdaq · Surgical & Medical Instruments & Apparatus
$9.24+2.33%close on Oct. 28, 2026 · volume 346K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 2, 2026 | Brenton Taylor EVP, Operations & R&D | Sold 10b5-1 plan | 2,988 | $8.85 | $26,453 |
| Oct. 2, 2026 | Alison Bauerlein Chief Operating Officer | Sold 10b5-1 plan | 25,260 | $8.85 | $223,627 |
| Oct. 2, 2026 | James Rodberg Chief Financial Officer | Sold 10b5-1 plan | 7,208 | $8.85 | $63,812 |
| Oct. 1, 2026 | David Badawi Chief Technology Officer, director | Sold 10b5-1 plan | 7,797 | $9.05 | $70,555 |
| Oct. 1, 2026 | Paul Badawi President and CEO, director, 10% owner | Sold 10b5-1 plan | 29,653 | $9.05 | $268,330 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 9 →Departure/appointment of directors or officers